The Health & Aging Brain Study - Health Disparities (HABS-HD)

健康

基本信息

批准号：
10708862
负责人：
LEIGH A JOHNSON
金额：
$ 2770.91万
依托单位：
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-30 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10708862
关键词：
Aducanumab Adult Affect African American African American population Age Aging Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Alzheimer&apos s disease risk Alzheimer’s disease biomarker Amyloid Area Biological Biological Markers Biostatistics Core Blood Blood Vessels Clinic Clinical Clinical Trials Communities Complement Data Data Analyses Development Disparity Enrollment Ensure Environmental Risk Factor Ethnic Origin Ethnic Population Etiology Genetic Genome Goals Guidelines Health Health Disparities Research Hispanic Hispanic Populations Image Individual Inflammatory Informatics Life Cycle Stages Liquid substance Longitudinal cohort Magnetic Resonance Imaging Medical Metabolic Methods Mexican Americans Neuropsychology Not Hispanic or Latino Participant Pathway interactions Pharmaceutical Preparations Population Population Heterogeneity Positron-Emission Tomography Prevention strategy Proteome Race Research Sampling Science Scientist Structure Therapeutic Training United States National Institutes of Health Visit aging brain cohort deprivation exosome experience genomic data health disparity health goals indexing metabolome neighborhood disadvantage neuroimaging next generation novel novel strategies outreach precision medicine programs racial population recruit social culture social factors sociocultural determinant tau Proteins treatment strategy

项目摘要

HABS-HD OVERALL ABSTRACT The 2018 AT(N) framework provided the field with the first biological conceptualization of Alzheimer’s disease (AD) for the explicit purpose of advancing clinical trials. In fact, the first amyloid-lowering drug (aducanumab) has now received FDA clearance. However, nearly all data supporting the framework itself, as well as clinical trials, comes from research among non-Hispanic white (NHW) individuals. By 2060 the U.S. will become largely “non-white” with 15% of the population being African American (AA) and 27.5% being Hispanic (65% of which are Mexican American [MA]). Therefore, there is an urgent need to understand the relevance of the AT(N) framework, and associated biomarker-based therapeutics, for 43% of the U.S. population. AAs currently have the highest burden of AD and AD related dementias (ADRD) while Hispanics will experience the greatest increase in AD/ADRDs by 2060. Moreover, Milestone 1 of the NIA AD+ADRD Implementation Milestones explicitly call for examination of “early mechanistic pathways of multiple etiologies” (1.I), sociocultural (1.I) and exposome (1.B) factors among community-based cohorts that include cutting edge imaging, fluid, genetic and other biomarkers in diverse populations to understand health disparities in AD. The Health & Aging Brain Study – Health Disparities (HABS-HD) is the first large-scale, community-based project to simultaneously study each of the AT(N) defined biomarkers, in alignment with the NIA Health Disparities Research Framework, across the three most prevalent racial/ethnic groups in the U.S., AA, MA, and NHW. The Aims of the HABS-HD U19 are as follows: Aim 1: To collect imaging, clinical, biological and genetic data which will result in the largest longitudinal cohort of diverse populations that examines AT(N) biomarkers across adulthood. Aim 2: To collect life-course exposome (via the Area Deprivation Index), as well as sociocultural data and examine how these factors affect the timing, sequence and trajectories of AT(N) biomarkers among diverse populations. Aim 3: To disseminate HABS-HD data and samples to the global scientific community. HABS-HD data will be made available via LONI while biofluid samples will be made available through the HABS-HD Omics Core. Genomics data will be made available per NIH/NIA guidelines. The long-term goal of HABS-HD is to establish population- specific informed precision medicine for novel treatment and prevention strategies for AD. To advance this goal, we will conduct the following Projects: Project 1) Examine the timing, sequence and trajectories of AT(N) biomarkers across diverse populations; Project 2) Examine the impact of vascular, metabolic and inflammatory factors on the timing, sequence and trajectories of AT(N) biomarkers across diverse populations; and Project 3) Examine the impact of the exposome (via neighborhood disadvantage) and sociocultural factors on the timing, sequence and trajectories of AT(N) biomarkers across diverse populations.

HABS-HD总体抽象 2018年（n）框架为该领域提供了对阿尔茨海默氏病的首个生物学概念化（AD）出于明确的目的进行临床试验。实际上，第一种降低淀粉样蛋白的药物（aducanumab）现在已经收到了FDA的许可。但是，几乎所有支持框架本身的数据以及临床试验来自非西班牙裔白人（NHW）个体的研究。到2060年，美国将成为主要是“非白人”，有15％的人口是非裔美国人（AA），27.5％是西班牙裔（占65％这是墨西哥裔美国人[MA]）。因此，迫切需要了解在（N）框架以及相关的基于生物标志物的治疗中，美国43％的人口。目前AAS 在AD和AD相关的痴呆症（ADRD）中，西班牙裔将经历最大的摄入症（ADRD）到2060年，AD/ADRD的增加。此外，NIA AD+ADRD实施里程碑的里程碑1 明确呼吁检查“多种病因的早期机械途径”（1.i），社会文化（1.i）和基于社区的同类群体中的杂物组（1.b）因素，包括尖端成像，流体，遗传和潜水员种群中的其他生物标志物了解AD的健康差异。健康与衰老的大脑研究 - 健康差异（HABS-HD）是首个简单研究的大规模，社区的项目 AT（N）定义的每个生物标志物都与NIA健康差异研究框架保持一致在美国，AA，MA和NHW的三个最普遍的种族/族裔中。 HABS-HD的目的 U19如下：目标1：收集成像，临床，生物学和遗传数据，这将导致在成年期（N）生物标志物检查的最大纵向人群。目标2：到收集生命课程的宣传组（通过该地区剥夺指数）以及社会文化数据，并研究如何这些因素会影响潜水员种群中AT（N）生物标志物的时间，顺序和轨迹。目的 3：将HABS-HD数据和样本传播到全球科学界。 HABS-HD数据将被制作可通过LONI获得，而生物流体样品将通过HABS-HD Omics Core提供。基因组学数据将根据NIH/NIA指南提供。 HABS-HD的长期目标是建立人口 - 针对AD的新型治疗和预防策略的特定知情精度。推进这一点目标，我们将进行以下项目：项目1）检查（n）的时间，顺序和轨迹潜水员种群的生物标志物；项目2）检查血管，代谢和炎症的影响 AT（N）生物标志物的时间，序列和轨迹的因素；和项目 3）检查杂物体（通过邻里灾难）和社会文化因素对 AT（N）生物标志物的时机，序列和轨迹遍及大多学生人群。